Atlas Trials

Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients

Clinical trial NCT04418401 · COMPLETED

Trial details

NCT number
NCT04418401
Sponsor
Zhejiang University
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2020-06-11
Primary completion
2025-11-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.